APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hyperimmune Globulin Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hyperimmune Globulin Injection Market Outlook and Growth Opportunities 2026

21 December 2025191 pages

Choose your research edition.

Industry ResearchHyperimmune Globulin Injection Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Hyperimmune Globulin Injection Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Hyperimmune Globulin Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hyperimmune Globulin Injection Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hyperimmune Globulin Injection Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Hyperimmune Globulin Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hyperimmune Globulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hyperimmune Globulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hyperimmune Globulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hyperimmune Globulin Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hyperimmune Globulin Injection market include CNBG, Sichuan Yuanda Shuyang, Shanghai RAAS, Hualan Bio, CBPO, Kedrion, Kamada, Grifols and Emergent, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hyperimmune Globulin Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hyperimmune Globulin Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hyperimmune Globulin Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hyperimmune Globulin Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Hyperimmune Globulin Injection Segment by Company

CNBG

Sichuan Yuanda Shuyang

Shanghai RAAS

Hualan Bio

CBPO

Kedrion

Kamada

Grifols

Emergent

CSL Behring

Biotest

ADMA Biologics

Hyperimmune Globulin Injection Segment by Type

Hepatitis B Immuneglobulins

Tetanus Toxin Immuneglobulins

Rabies Immuneglobulins

Rho(D) Immune Globulin

Cytomegalovirus Immune Globulin

Varicella-Zoster Immune Globulin

Others

Hyperimmune Globulin Injection Segment by Application

Government Institution

Private Sector

Others

Hyperimmune Globulin Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hyperimmune Globulin Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hyperimmune Globulin Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hyperimmune Globulin Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Hyperimmune Globulin Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hyperimmune Globulin Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hyperimmune Globulin Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hyperimmune Globulin Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hyperimmune Globulin Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hyperimmune Globulin Injection industry.

Chapter 3: Detailed analysis of Hyperimmune Globulin Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hyperimmune Globulin Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hyperimmune Globulin Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hyperimmune Globulin Injection Industry Trends Table 2. Hyperimmune Globulin Injection Industry Drivers Table 3. Hyperimmune Globulin Injection Industry Opportunities and Challenges Table 4. Hyperimmune Globulin Injection Industry Restraints Table 5. Global Hyperimmune Globulin Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hyperimmune Globulin Injection Revenue Share by Company (2021-2026) Table 7. Global Hyperimmune Globulin Injection Sales Volume by Company (k units) & (2021-2026) Table 8. Global Hyperimmune Globulin Injection Sales Volume Share by Company (2021-2026) Table 9. Global Hyperimmune Globulin Injection Average Price (US$/unit) of Company (2021-2026) Table 10. Global Hyperimmune Globulin Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hyperimmune Globulin Injection Key Company Manufacturing Base & Headquarters Table 12. Global Hyperimmune Globulin Injection Company, Product Type & Application Table 13. Global Hyperimmune Globulin Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hyperimmune Globulin Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Hepatitis B Immuneglobulins Table 18. Significant Companies of Tetanus Toxin Immuneglobulins Table 19. Significant Companies of Rabies Immuneglobulins Table 20. Significant Companies of Rho(D) Immune Globulin Table 21. Significant Companies of Cytomegalovirus Immune Globulin Table 22. Significant Companies of Varicella-Zoster Immune Globulin Table 23. Significant Companies of Others Table 24. Global Hyperimmune Globulin Injection Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Hyperimmune Globulin Injection Sales Volume by Type (2021-2026) & (k units) Table 26. Global Hyperimmune Globulin Injection Sales Volume by Type (2027-2032) & (k units) Table 27. Global Hyperimmune Globulin Injection Sales Volume Share by Type (2021-2026) Table 28. Global Hyperimmune Globulin Injection Sales Volume Share by Type (2027-2032) Table 29. Global Hyperimmune Globulin Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Hyperimmune Globulin Injection Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Hyperimmune Globulin Injection Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Hyperimmune Globulin Injection Sales Value Share by Type (2021-2026) Table 33. Global Hyperimmune Globulin Injection Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Government Institution Table 35. Significant Companies of Private Sector Table 36. Significant Companies of Others Table 37. Global Hyperimmune Globulin Injection Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Hyperimmune Globulin Injection Sales Volume by Application (2021-2026) & (k units) Table 39. Global Hyperimmune Globulin Injection Sales Volume by Application (2027-2032) & (k units) Table 40. Global Hyperimmune Globulin Injection Sales Volume Share by Application (2021-2026) Table 41. Global Hyperimmune Globulin Injection Sales Volume Share by Application (2027-2032) Table 42. Global Hyperimmune Globulin Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Hyperimmune Globulin Injection Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Hyperimmune Globulin Injection Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Hyperimmune Globulin Injection Sales Value Share by Application (2021-2026) Table 46. Global Hyperimmune Globulin Injection Sales Value Share by Application (2027-2032) Table 47. Global Hyperimmune Globulin Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Hyperimmune Globulin Injection Sales by Region (2021-2026) & (k units) Table 49. Global Hyperimmune Globulin Injection Sales Market Share by Region (2021-2026) Table 50. Global Hyperimmune Globulin Injection Sales by Region (2027-2032) & (k units) Table 51. Global Hyperimmune Globulin Injection Sales Market Share by Region (2027-2032) Table 52. Global Hyperimmune Globulin Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Hyperimmune Globulin Injection Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Hyperimmune Globulin Injection Sales Value Share by Region (2021-2026) Table 55. Global Hyperimmune Globulin Injection Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Hyperimmune Globulin Injection Sales Value Share by Region (2027-2032) Table 57. Global Hyperimmune Globulin Injection Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Hyperimmune Globulin Injection Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Hyperimmune Globulin Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Hyperimmune Globulin Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Hyperimmune Globulin Injection Sales by Country (2021-2026) & (k units) Table 62. Global Hyperimmune Globulin Injection Sales Market Share by Country (2021-2026) Table 63. Global Hyperimmune Globulin Injection Sales by Country (2027-2032) & (k units) Table 64. Global Hyperimmune Globulin Injection Sales Market Share by Country (2027-2032) Table 65. Global Hyperimmune Globulin Injection Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Hyperimmune Globulin Injection Sales Value Market Share by Country (2021-2026) Table 67. Global Hyperimmune Globulin Injection Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Hyperimmune Globulin Injection Sales Value Market Share by Country (2027-2032) Table 69. CNBG Company Information Table 70. CNBG Business Overview Table 71. CNBG Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. CNBG Hyperimmune Globulin Injection Product Portfolio Table 73. CNBG Recent Development Table 74. Sichuan Yuanda Shuyang Company Information Table 75. Sichuan Yuanda Shuyang Business Overview Table 76. Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Product Portfolio Table 78. Sichuan Yuanda Shuyang Recent Development Table 79. Shanghai RAAS Company Information Table 80. Shanghai RAAS Business Overview Table 81. Shanghai RAAS Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Shanghai RAAS Hyperimmune Globulin Injection Product Portfolio Table 83. Shanghai RAAS Recent Development Table 84. Hualan Bio Company Information Table 85. Hualan Bio Business Overview Table 86. Hualan Bio Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Hualan Bio Hyperimmune Globulin Injection Product Portfolio Table 88. Hualan Bio Recent Development Table 89. CBPO Company Information Table 90. CBPO Business Overview Table 91. CBPO Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. CBPO Hyperimmune Globulin Injection Product Portfolio Table 93. CBPO Recent Development Table 94. Kedrion Company Information Table 95. Kedrion Business Overview Table 96. Kedrion Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Kedrion Hyperimmune Globulin Injection Product Portfolio Table 98. Kedrion Recent Development Table 99. Kamada Company Information Table 100. Kamada Business Overview Table 101. Kamada Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Kamada Hyperimmune Globulin Injection Product Portfolio Table 103. Kamada Recent Development Table 104. Grifols Company Information Table 105. Grifols Business Overview Table 106. Grifols Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Grifols Hyperimmune Globulin Injection Product Portfolio Table 108. Grifols Recent Development Table 109. Emergent Company Information Table 110. Emergent Business Overview Table 111. Emergent Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Emergent Hyperimmune Globulin Injection Product Portfolio Table 113. Emergent Recent Development Table 114. CSL Behring Company Information Table 115. CSL Behring Business Overview Table 116. CSL Behring Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. CSL Behring Hyperimmune Globulin Injection Product Portfolio Table 118. CSL Behring Recent Development Table 119. Biotest Company Information Table 120. Biotest Business Overview Table 121. Biotest Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Biotest Hyperimmune Globulin Injection Product Portfolio Table 123. Biotest Recent Development Table 124. ADMA Biologics Company Information Table 125. ADMA Biologics Business Overview Table 126. ADMA Biologics Hyperimmune Globulin Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. ADMA Biologics Hyperimmune Globulin Injection Product Portfolio Table 128. ADMA Biologics Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Hyperimmune Globulin Injection Distributors List Table 132. Hyperimmune Globulin Injection Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Hyperimmune Globulin Injection Product Image Figure 2. Global Hyperimmune Globulin Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hyperimmune Globulin Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hyperimmune Globulin Injection Sales (2021-2032) & (k units) Figure 5. Global Hyperimmune Globulin Injection Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Hyperimmune Globulin Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Hepatitis B Immuneglobulins Image Figure 10. Tetanus Toxin Immuneglobulins Image Figure 11. Rabies Immuneglobulins Image Figure 12. Rho(D) Immune Globulin Image Figure 13. Cytomegalovirus Immune Globulin Image Figure 14. Varicella-Zoster Immune Globulin Image Figure 15. Others Image Figure 16. Global Hyperimmune Globulin Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Hyperimmune Globulin Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Hyperimmune Globulin Injection Sales Volume Share by Type (2021-2032) Figure 19. Global Hyperimmune Globulin Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Hyperimmune Globulin Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Hyperimmune Globulin Injection Sales Value Share by Type (2021-2032) Figure 22. Government Institution Image Figure 23. Private Sector Image Figure 24. Others Image Figure 25. Global Hyperimmune Globulin Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Hyperimmune Globulin Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Hyperimmune Globulin Injection Sales Volume Share by Application (2021-2032) Figure 28. Global Hyperimmune Globulin Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Hyperimmune Globulin Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Hyperimmune Globulin Injection Sales Value Share by Application (2021-2032) Figure 31. Global Hyperimmune Globulin Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Hyperimmune Globulin Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Hyperimmune Globulin Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Hyperimmune Globulin Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Hyperimmune Globulin Injection Sales Value (2021-2032) & (US$ Million) Figure 36. North America Hyperimmune Globulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Hyperimmune Globulin Injection Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Hyperimmune Globulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Hyperimmune Globulin Injection Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Hyperimmune Globulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Hyperimmune Globulin Injection Sales Value (2021-2032) & (US$ Million) Figure 42. South America Hyperimmune Globulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Hyperimmune Globulin Injection Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Hyperimmune Globulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Hyperimmune Globulin Injection Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Hyperimmune Globulin Injection Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Hepatitis B Immuneglobulins
  • Tetanus Toxin Immuneglobulins
  • Rabies Immuneglobulins
  • Rho(D) Immune Globulin
  • Cytomegalovirus Immune Globulin
  • Varicella-Zoster Immune Globulin
  • Others
Applications
  • Government Institution
  • Private Sector
  • Others
Companies covered
  • CNBG
  • Sichuan Yuanda Shuyang
  • Shanghai RAAS
  • Hualan Bio
  • CBPO
  • Kedrion
  • Kamada
  • Grifols
  • Emergent
  • CSL Behring
  • Biotest
  • ADMA Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hyperimmune Globulin Injection Sales Value (2021-2032)
  4. 1.2.2 Global Hyperimmune Globulin Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Hyperimmune Globulin Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hyperimmune Globulin Injection Market Dynamics
  1. 2.1 Hyperimmune Globulin Injection Industry Trends
  2. 2.2 Hyperimmune Globulin Injection Industry Drivers
  3. 2.3 Hyperimmune Globulin Injection Industry Opportunities and Challenges
  4. 2.4 Hyperimmune Globulin Injection Industry Restraints
3 Hyperimmune Globulin Injection Market by Company
  1. 3.1 Global Hyperimmune Globulin Injection Company Revenue Ranking in 2025
  2. 3.2 Global Hyperimmune Globulin Injection Revenue by Company (2021-2026)
  3. 3.3 Global Hyperimmune Globulin Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Hyperimmune Globulin Injection Average Price by Company (2021-2026)
  5. 3.5 Global Hyperimmune Globulin Injection Company Ranking (2024-2026)
  6. 3.6 Global Hyperimmune Globulin Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Hyperimmune Globulin Injection Company Product Type and Application
  8. 3.8 Global Hyperimmune Globulin Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hyperimmune Globulin Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hyperimmune Globulin Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hyperimmune Globulin Injection Market by Type
  1. 4.1 Hyperimmune Globulin Injection Type Introduction
  2. 4.1.1 Hepatitis B Immuneglobulins
  3. 4.1.2 Tetanus Toxin Immuneglobulins
  4. 4.1.3 Rabies Immuneglobulins
  5. 4.1.4 Rho(D) Immune Globulin
  6. 4.1.5 Cytomegalovirus Immune Globulin
  7. 4.1.6 Varicella-Zoster Immune Globulin
  8. 4.1.7 Others
  9. 4.2 Global Hyperimmune Globulin Injection Sales Volume by Type
  10. 4.2.1 Global Hyperimmune Globulin Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Hyperimmune Globulin Injection Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Hyperimmune Globulin Injection Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Hyperimmune Globulin Injection Sales Value by Type
  14. 4.3.1 Global Hyperimmune Globulin Injection Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Hyperimmune Globulin Injection Sales Value by Type (2021-2032)
  16. 4.3.3 Global Hyperimmune Globulin Injection Sales Value Share by Type (2021-2032)
5 Hyperimmune Globulin Injection Market by Application
  1. 5.1 Hyperimmune Globulin Injection Application Introduction
  2. 5.1.1 Government Institution
  3. 5.1.2 Private Sector
  4. 5.1.3 Others
  5. 5.2 Global Hyperimmune Globulin Injection Sales Volume by Application
  6. 5.2.1 Global Hyperimmune Globulin Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hyperimmune Globulin Injection Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hyperimmune Globulin Injection Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hyperimmune Globulin Injection Sales Value by Application
  10. 5.3.1 Global Hyperimmune Globulin Injection Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hyperimmune Globulin Injection Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hyperimmune Globulin Injection Sales Value Share by Application (2021-2032)
6 Hyperimmune Globulin Injection Regional Sales and Value Analysis
  1. 6.1 Global Hyperimmune Globulin Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hyperimmune Globulin Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Hyperimmune Globulin Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Hyperimmune Globulin Injection Sales by Region (2027-2032)
  5. 6.3 Global Hyperimmune Globulin Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hyperimmune Globulin Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hyperimmune Globulin Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hyperimmune Globulin Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Hyperimmune Globulin Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hyperimmune Globulin Injection Sales Value (2021-2032)
  12. 6.6.2 North America Hyperimmune Globulin Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hyperimmune Globulin Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Hyperimmune Globulin Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hyperimmune Globulin Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hyperimmune Globulin Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hyperimmune Globulin Injection Sales Value (2021-2032)
  21. 6.9.2 South America Hyperimmune Globulin Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hyperimmune Globulin Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hyperimmune Globulin Injection Sales Value Share by Country, 2025 VS 2032
7 Hyperimmune Globulin Injection Country-level Sales and Value Analysis
  1. 7.1 Global Hyperimmune Globulin Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hyperimmune Globulin Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hyperimmune Globulin Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Hyperimmune Globulin Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Hyperimmune Globulin Injection Sales by Country (2027-2032)
  6. 7.4 Global Hyperimmune Globulin Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hyperimmune Globulin Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hyperimmune Globulin Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hyperimmune Globulin Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hyperimmune Globulin Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hyperimmune Globulin Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CNBG
  2. 8.1.1 CNBG Company Information
  3. 8.1.2 CNBG Business Overview
  4. 8.1.3 CNBG Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CNBG Hyperimmune Globulin Injection Product Portfolio
  6. 8.1.5 CNBG Recent Developments
  7. 8.2 Sichuan Yuanda Shuyang
  8. 8.2.1 Sichuan Yuanda Shuyang Company Information
  9. 8.2.2 Sichuan Yuanda Shuyang Business Overview
  10. 8.2.3 Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Product Portfolio
  12. 8.2.5 Sichuan Yuanda Shuyang Recent Developments
  13. 8.3 Shanghai RAAS
  14. 8.3.1 Shanghai RAAS Company Information
  15. 8.3.2 Shanghai RAAS Business Overview
  16. 8.3.3 Shanghai RAAS Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai RAAS Hyperimmune Globulin Injection Product Portfolio
  18. 8.3.5 Shanghai RAAS Recent Developments
  19. 8.4 Hualan Bio
  20. 8.4.1 Hualan Bio Company Information
  21. 8.4.2 Hualan Bio Business Overview
  22. 8.4.3 Hualan Bio Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hualan Bio Hyperimmune Globulin Injection Product Portfolio
  24. 8.4.5 Hualan Bio Recent Developments
  25. 8.5 CBPO
  26. 8.5.1 CBPO Company Information
  27. 8.5.2 CBPO Business Overview
  28. 8.5.3 CBPO Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CBPO Hyperimmune Globulin Injection Product Portfolio
  30. 8.5.5 CBPO Recent Developments
  31. 8.6 Kedrion
  32. 8.6.1 Kedrion Company Information
  33. 8.6.2 Kedrion Business Overview
  34. 8.6.3 Kedrion Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kedrion Hyperimmune Globulin Injection Product Portfolio
  36. 8.6.5 Kedrion Recent Developments
  37. 8.7 Kamada
  38. 8.7.1 Kamada Company Information
  39. 8.7.2 Kamada Business Overview
  40. 8.7.3 Kamada Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Kamada Hyperimmune Globulin Injection Product Portfolio
  42. 8.7.5 Kamada Recent Developments
  43. 8.8 Grifols
  44. 8.8.1 Grifols Company Information
  45. 8.8.2 Grifols Business Overview
  46. 8.8.3 Grifols Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Grifols Hyperimmune Globulin Injection Product Portfolio
  48. 8.8.5 Grifols Recent Developments
  49. 8.9 Emergent
  50. 8.9.1 Emergent Company Information
  51. 8.9.2 Emergent Business Overview
  52. 8.9.3 Emergent Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Emergent Hyperimmune Globulin Injection Product Portfolio
  54. 8.9.5 Emergent Recent Developments
  55. 8.10 CSL Behring
  56. 8.10.1 CSL Behring Company Information
  57. 8.10.2 CSL Behring Business Overview
  58. 8.10.3 CSL Behring Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 CSL Behring Hyperimmune Globulin Injection Product Portfolio
  60. 8.10.5 CSL Behring Recent Developments
  61. 8.11 Biotest
  62. 8.11.1 Biotest Company Information
  63. 8.11.2 Biotest Business Overview
  64. 8.11.3 Biotest Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Biotest Hyperimmune Globulin Injection Product Portfolio
  66. 8.11.5 Biotest Recent Developments
  67. 8.12 ADMA Biologics
  68. 8.12.1 ADMA Biologics Company Information
  69. 8.12.2 ADMA Biologics Business Overview
  70. 8.12.3 ADMA Biologics Hyperimmune Globulin Injection Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 ADMA Biologics Hyperimmune Globulin Injection Product Portfolio
  72. 8.12.5 ADMA Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hyperimmune Globulin Injection Value Chain Analysis
  2. 9.1.1 Hyperimmune Globulin Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hyperimmune Globulin Injection Sales Mode & Process
  6. 9.2 Hyperimmune Globulin Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hyperimmune Globulin Injection Distributors
  9. 9.2.3 Hyperimmune Globulin Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst